High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

Rhee, Jiyoung

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. [electronic resource] - Breast cancer research and treatment Jan 2011 - 107-14 p. digital

Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1573-7217

10.1007/s10549-010-1200-9 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--blood
Breast Neoplasms--blood
Capecitabine
Cell Line, Tumor
Cell Proliferation--drug effects
Chi-Square Distribution
Deoxycytidine--administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Enzyme-Linked Immunosorbent Assay
Female
Fluorouracil--administration & dosage
Humans
Kaplan-Meier Estimate
Lapatinib
Logistic Models
Middle Aged
Quinazolines--administration & dosage
Receptor, ErbB-2--metabolism
Republic of Korea
Risk Assessment
Risk Factors
Time Factors
Transforming Growth Factor alpha--blood
Treatment Outcome
Up-Regulation